Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY26 Earnings Presentation
19 slides from Gland Pharma's earnings presentation, Jan 28, 2026
Slide 1: Exchange filing cover letter for Q3FY26 investor presentation
GLAND PHARMA LIMITED January 28, 2026 January 28, 2026 BSE Limited BSE Limited National National Stock Stock Exchange Exchange of of India India Limited Limited Corporate Relationship Corporate Relationship Department Department Listing Listing Department Department Phiroze Jeejeebhoy Phiroze Jeejee
Slide 2: Investor Presentation Q3 & 9M FY26
GLANDI GLAND PHARMA Investor Presentation Presentation Q3 & Q3 & 9M 9M FY26 FY26 28 January 2026
Slide 3: Safe Harbour Statement
Safe Safe Harbour Harbour Statement Statement The The Presentation Presentation is is to to provide provide the the general general background background information information about about the the Company’s activities Company’s activities as as at at the the date date of of the the Presentation. Pr
Slide 4: Financial Highlights
GLAND Financial Highlights Financial Highlights
Slide 5: Consolidated P&L Highlights
Consolidated Consolidated P&L P&L Highlights Highlights ₹ Mn ?Mn Particulars Particulars Q3 Q3 FY26 FY26 Q3 FY25 Q3 FY25 YoY YoY Q2 Q2 FY26 FY26 QoQ QoQ 9M FY26 9M FY26 9M 9M FY25 FY25 YoY YoY Revenue Revenue from from operations operations 16,954 16,954 13,841 13,841 22% 22% 14,869 14,869 14% 14% 4
Slide 6: Consolidated Financial Highlights
Consolidated Consolidated Financial Financial Highlights Highlights Revenue Revenue from from Operations Operations Gross Gross Profit *1> / Gross Profit (1) Gross Profit Profit Margin <2) Margin (2) (₹ (? Mn) Mn) (₹ (? Mn Mn I/ %) %) 46,879 46,879 30,363 30,363 41,916 41,916 25,892 25,892 65% 62% 1
Slide 7: Base Business (Gland) P&L Highlights
Base Base Business (Gland) P&L Business (Gland) P&L Highlights Highlights ₹ Mn ?Mn Particulars Particulars Q3 Q3 FY26 FY26 Q3 Q3 FY25 FY25 YoY YoY Q2 Q2 FY26 FY26 QoQ QoQ 9M 9M FY26 FY26 9M 9M FY25 FY25 YoY YoY Revenue Revenue from from operations operations 11,790 11,790 10,123 10,123 16% 16% 10,76
Slide 8: Base Business (Gland) Financial Highlights
Base Base Business (Gland) Financial Business (Gland) Financial Highlights Highlights Revenue R e v e n u e from from Operations Operations Gross Gross Profit *1> // Gross Profit (1) Gross Profit Profit Margin *2) Margin (2) (₹ Mn) (₹ (< Mn Mn // %) %) 32,965 32,965 30,917 30,917 19,862 19,862 17,66
Slide 9: Group Financial Highlights (1/2)
Group Group Financial Financial Highlights Highlights (1/2) (1/2) (1) Net Net Worth Worth <1 > ROCE (2) ROCE (2) O N W (3) // RRONW (3) (₹ Mn) (? (%) (%) RoCE RoNW 87,238 91,507 98,789 11% 11% 15.00% 11% 11% 9% 10.00% 9% 9% 8% 5.00% 0.00% FY24 FY25 9M FY26 FY24 FY25 9M FY26 Capital Capital Expenditu
Slide 10: Group Financial Highlights (2/2)
Group Group Financial Financial Highlights Highlights (2/2) (2/2) * Cash Cash and and Bank Bank Balances Balances // Net Cash (1) Net Cash Cash Cash Flow from Operations Flow from Operations (₹ ■■Total Total Cash (₹ (? Mn) Mn) (? Mn) Mn) Net Cash 26,565 6,228 6,228 5,889 5,889 6,269 6 269 ’ 25,562 2
Slide 11: Business Update
GLAND Business Update Business Update
Slide 12: Base Business (Gland) Updates
Base Base Business Business (Gland) Updates (Gland) Updates • •; • • R&D Expenses: Total Total R&D expenses were ₹650 650 million in Q3 FY26, representing 5.4% of revenue versus ₹437 437 million, representing 4.3% of revenues, in Q3 FY25. The increase in R&D is on account of complex product developm
Slide 13: Cenexi Updates
Cenexi Cenexi Updates Updates Q3 FY26 Q3 FY25 Q2 FY26 9M FY26 9M FY25 Particulars Particulars YoY QoQ QoQ YoY € Mn. € Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ? Mn. € Mn. € Mn. ₹ Mn. ? Mn. € € Mn. Mn. ₹ Mn. ? Mn. € Mn. € Mn. ₹ Mn. ? Mn. Revenue from operations 50 50 5,164 41 3,717 39% 39% 40 40 4,102 26% 26
Slide 14: Geographical Revenue
GLAND Geographical Geographical Revenue
Slide 15: US Market
US US Market Market t₹MMn n Group Revenue Contribution Gland Gland Cenexi 19% YoY i 9% YoY 16% YoY i 6% YoY 150% YoY 126% 126% YoY YoY 22,052 23,466 941 22,469 24,407 24,407 8,005 8,290 395 417 7,293 8,279 8,685 8,685 7,135 8,290 274 158 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY2
Slide 16: Europe Market
Europe Europe Market Market ?₹ Mn Mn Group Revenue Contribution Gland Cenexi 54% YoY 33% YoY 42% YoY 23% YoY 56% YoY 35% YoY 1,421 8,800 10,221 1,155 6,517 7,672 593 3,478 2,847 4,071 419 2,227 2,658 2,646 189 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2
Slide 17: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, (Canada, Australia Australia and and New Zealand) New Zealand) t₹MMn n Group Revenue Contribution Gland Cenexi -1% YoY 18% YoY -15% YoY 10% YoY 37% YoY 34% YoY 1,680 647 1,420 1,033 937 483 459 488 454 338 273 288 215 166 121 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY2
Slide 18: Rest of the World
Rest of the Rest of the World World ?₹ Mn Mn Group Revenue Group Contribution Revenue Contribution Gland Gland Cenexi Cenexi 4% YoY 2% YoY 12% YoY 4% YoY -7% YoY -2% YoY Own Products ■ TT & CMO TT&CMO ■ 4,810 5,044 5,044 8,392 8,568 3,582 3,524 ! | l ,1,023 023 704 704 2,881 2,590 3,000 1,669 1,635
Slide 19: Thank You
iGiANPl GLAND PHARMA Thank You Thank You Corporate Office Investor Relations: Gland Gland Pharma Pharma Limited Limited Sampath Sampath Kumar Kumar Pallerlamudi Pallerlamudi Plot Plot No. No. 11 11 & & 84, 84, TSIIC TSIIC Phase: Phase: IV IV Company Company Secretary Secretary & & Compliance Complia